Bentley Pharmaceuticals Names Richard P. Lindsay Vice President and CFO

EXETER, N.H., Sept. 11 /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc. , a specialty pharmaceutical company, announced the appointment of Richard P. Lindsay as the Company's Vice President and Chief Financial Officer, effective immediately. Mr. Lindsay succeeds Michael Price, who has resigned to pursue other opportunities closer to his new home and family in Florida.

"We are very excited to have Richard join our senior management team," said John Sedor, President of Bentley. "He has a proven track record in public companies managing global financial functions, operations and international business development functions. Specifically, his responsibilities have included financial reporting, capital formation, mergers and acquisitions and internal controls. Importantly, Richard is not only a versatile CFO, but also a remarkably thoughtful business strategist with broad based experience in operational management, sales and marketing and integrated business process redesign."

James Murphy, Chairman and CEO, commented, "Mike Price has been a valuable employee of Bentley for almost 15 years with various financial responsibilities as the Company grew its revenues from less than $20 million annually to our current profitable levels approaching $120 million. We all wish the best to Mike and his family in Florida." Mr. Murphy continued, "We are excited about Richard Lindsay's arrival because we believe he has the experience and enthusiasm to guide a financial strategy that can lead us into a new period of growth and prosperity for the benefit of our shareholders."

Mr. Lindsay brings 15 years of finance, treasury, accounting and management experience to Bentley. In addition to his audit and consulting background, Mr. Lindsay has held senior financial management roles at manufacturing companies ranging from newly-formed start-ups to well established public companies with global operations.

From 1997 to 2003, Mr. Lindsay progressed through several senior positions, including CFO and Director of International Business Development, at the NYSE-listed Boston Beer Company. During his tenure at the company, Mr. Lindsay was responsible for all finance, IT and business development functions. He has also held senior finance positions at StockerYale, a Nasdaq-listed photonics company, and Agility, a contract manufacturer. He started his career in public accounting at KPMG Peat Marwick in 1992. From 1981 to 1989, Mr. Lindsay served in the U.S. Navy, Submarine Service.

Mr. Lindsay holds an MBA (Honors) from Northeastern University and a B.S. in Management with a concentration in Accounting and a minor in Economics from the University of Massachusetts. He is a Certified Public Accountant (CPA).

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and generic pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures a growing portfolio of generic and branded generic pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiary, Laboratorios Belmac, and markets these pharmaceutical products through its subsidiaries, Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Additional information regarding Bentley Pharmaceuticals' may be obtained through Bentley's web site at http://www.bentleypharm.com/.

Contact: Bentley Pharmaceuticals, Inc. John Sedor, President James Murphy, Chairman & CEO 603.658.6100